TypPharma
Molecular Therapeutics
Lab Core Active
Target Phenotype 01 / 03
Typ-Alpha // Oncology
Targeted Receptor Ligand
Cell-selective intracellular delivery system for treatment-resistant solid tumors.
Typ-Beta // Neuro-Degeneration
Neural Proteostasis Factor
High-affinity molecular chaperone mitigating toxic protein aggregation in CNS tissues.
Typ-Gamma // Autoimmune
Cytokine Receptor Modulator
Precision pathway inhibitor preventing hyper-inflammatory signaling cascades.
TYP-ONCO-99
Ligand Bound

Targeted Receptor Ligand

Engineered for precise phenotypic receptor affinity. Minimizes off-target cytotoxicity while maximizing cellular therapeutic absorption.

Binding Affinity 99.8 Ki
Target Specificity 98.4%
Cell Uptake Rate 94.1%
Trial Phase Phase III